Yifan Pharmaceutical Co Ltd
SZSE:002019
P/OCF
Price to OCF
Price to Operating Cash Flow (P/OCF) ratio is a valuation multiple that measures the value of a company’s market capitalization relative to the operating cash flow it generates. Some analysts prefer P/OCF over P/E since earnings can be more easily manipulated than cash flows.
Market Cap | P/OCF | ||||
---|---|---|---|---|---|
CN |
Y
|
Yifan Pharmaceutical Co Ltd
SZSE:002019
|
16.6B CNY | 31.5 | |
JP |
N
|
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
|
776 550.9T JPY | -19 905 436.7 | |
US |
Eli Lilly and Co
NYSE:LLY
|
744.3B USD | 206.7 | ||
DK |
Novo Nordisk A/S
CSE:NOVO B
|
4.1T DKK | 43.7 | ||
UK |
Dechra Pharmaceuticals PLC
LSE:DPH
|
440.4B GBP | 6 923.9 | ||
US |
Johnson & Johnson
NYSE:JNJ
|
364.1B USD | 15.7 | ||
US |
Merck & Co Inc
NYSE:MRK
|
331.8B USD | 22.5 | ||
UK |
AstraZeneca PLC
LSE:AZN
|
189.2B GBP | 24.9 | ||
CH |
Roche Holding AG
SIX:ROG
|
188.1B CHF | 11.7 | ||
CH |
Novartis AG
SIX:NOVN
|
182.7B CHF | 14.6 | ||
US |
Pfizer Inc
NYSE:PFE
|
161.7B USD | 18.8 |
P/OCF Forward Multiples
Forward P/OCF multiple is a version of the P/OCF ratio that uses forecasted operating cash flow for the P/OCF calculation. 1-Year, 2-Years, and 3-Years forwards use operating cash flow forecasts for 1, 2, and 3 years ahead, respectively.